Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: where do we stand?
作者信息
Yip Pui Lam, Lee Shing Fung, Chua Melvin
机构信息
Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore.
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
出版信息
BMJ Oncol. 2025 Sep 2;4(1):e000894. doi: 10.1136/bmjonc-2025-000894. eCollection 2025.
Abstract
摘要
相似文献
1
Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: where do we stand?局部区域晚期鼻咽癌的辅助化疗：我们目前的状况如何？
BMJ Oncol. 2025 Sep 2;4(1):e000894. doi: 10.1136/bmjonc-2025-000894. eCollection 2025.
2
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.节拍式卡培他滨作为局部晚期鼻咽癌辅助治疗：一项多中心、开放标签、平行分组、随机、对照、3 期临床试验。
Lancet. 2021 Jul 24;398(10297):303-313. doi: 10.1016/S0140-6736(21)01123-5. Epub 2021 Jun 7.
3
A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.贝叶斯网状meta 分析比较局部晚期鼻咽癌患者同步放化疗后辅助化疗、单纯同步放化疗和单纯放疗的疗效。
Ann Oncol. 2015 Jan;26(1):205-211. doi: 10.1093/annonc/mdu507. Epub 2014 Oct 29.
4
Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis.局部晚期鼻咽癌的放化疗方案：一项贝叶斯网络荟萃分析。
Eur J Cancer. 2015 Aug;51(12):1570-9. doi: 10.1016/j.ejca.2015.04.027. Epub 2015 Jun 1.
5
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.托瑞帕利单抗用于局部晚期鼻咽癌的新辅助和辅助治疗：一项随机、单中心、双盲、安慰剂对照的2期试验。
Lancet Oncol. 2024 Dec;25(12):1563-1575. doi: 10.1016/S1470-2045(24)00504-7. Epub 2024 Nov 7.
6
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma.诱导吉西他滨和顺铂治疗局部晚期鼻咽癌。
Cancer Commun (Lond). 2019 Jun 25;39(1):39. doi: 10.1186/s40880-019-0385-5.
7
Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.免疫调节节拍卡培他滨辅助治疗局部晚期鼻咽癌的疗效。
BMC Immunol. 2024 May 6;25(1):28. doi: 10.1186/s12865-024-00621-3.
8
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.同期放化疗加辅助化疗与单纯同期放化疗治疗局部晚期鼻咽癌患者的随机对照 3 期多中心临床试验。
Lancet Oncol. 2012 Feb;13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5. Epub 2011 Dec 7.
9
Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.新辅助化疗联合调强放疗与同步放化疗联合辅助化疗治疗局部晚期鼻咽癌的回顾性对照研究
Chin J Cancer. 2016 Jan 6;35:2. doi: 10.1186/s40880-015-0076-9.
10
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.一项前瞻性随机试验的结果，该试验比较了新辅助化疗加放疗与单纯放疗在局部晚期鼻咽癌患者中的疗效。
J Clin Oncol. 2001 Mar 1;19(5):1350-7. doi: 10.1200/JCO.2001.19.5.1350.
本文引用的文献
1
Real-world experience on efficacy and safety of different adjuvant chemotherapy regimens in locoregionally advanced nasopharyngeal carcinoma.不同辅助化疗方案治疗局部区域晚期鼻咽癌的疗效和安全性的真实世界经验。
BMJ Oncol. 2025 Jul 21;4(1):e000718. doi: 10.1136/bmjonc-2024-000718. eCollection 2025.
2
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.高危N2至N3期鼻咽癌患者诱导化疗与辅助放化疗的比较：一项3期随机临床试验
JAMA Oncol. 2025 Jun 18. doi: 10.1001/jamaoncol.2025.1597.
3
Plasma Epstein-Barr Virus DNA Temporal Clearance Pattern During Induction-Concurrent (Chemo)Radiation Therapy for Risk Stratification in Nasopharyngeal Carcinoma.诱导同步（化疗）放疗期间血浆 Epstein-Barr 病毒 DNA 的时间清除模式用于鼻咽癌风险分层
Int J Radiat Oncol Biol Phys. 2025 Sep 1;123(1):129-140. doi: 10.1016/j.ijrobp.2025.03.076. Epub 2025 Apr 7.
4
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.托瑞帕利单抗用于局部晚期鼻咽癌的新辅助和辅助治疗：一项随机、单中心、双盲、安慰剂对照的2期试验。
Lancet Oncol. 2024 Dec;25(12):1563-1575. doi: 10.1016/S1470-2045(24)00504-7. Epub 2024 Nov 7.
5
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.中国局部晚期鼻咽癌患者同步诱导放化疗联合或不联合信迪利单抗（CONTINUUM）：一项多中心、开放标签、平行分组、随机、对照、III 期临床试验。
Lancet. 2024 Jun 22;403(10445):2720-2731. doi: 10.1016/S0140-6736(24)00594-4. Epub 2024 May 30.
6
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.同步放化疗后序贯顺铂-吉西他滨与顺铂-氟尿嘧啶化疗用于N2-3期鼻咽癌：一项多中心、开放标签、随机、对照、3期试验
Lancet Oncol. 2023 Jul;24(7):798-810. doi: 10.1016/S1470-2045(23)00232-2. Epub 2023 Jun 5.
7
Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis.放化疗在调强放疗治疗鼻咽癌患者中的作用（MAC-NPC）：一项更新的个体患者数据网络荟萃分析。
Lancet Oncol. 2023 Jun;24(6):611-623. doi: 10.1016/S1470-2045(23)00163-8.
8
Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial.局部晚期鼻咽癌同步放化疗后辅助卡培他滨治疗：一项随机临床试验
JAMA Oncol. 2022 Oct 13;8(12):1776-85. doi: 10.1001/jamaoncol.2022.4656.
9
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.吉西他滨和顺铂诱导化疗治疗鼻咽癌的最终总生存分析：一项多中心、随机 III 期试验。
J Clin Oncol. 2022 Aug 1;40(22):2420-2425. doi: 10.1200/JCO.22.00327. Epub 2022 Jun 16.
10
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.节拍式卡培他滨作为局部晚期鼻咽癌辅助治疗：一项多中心、开放标签、平行分组、随机、对照、3 期临床试验。
Lancet. 2021 Jul 24;398(10297):303-313. doi: 10.1016/S0140-6736(21)01123-5. Epub 2021 Jun 7.
Zotero 插件